Spectrum Pharmaceuticals, Inc.  (NASDAQ:$SPPI) is a biotechnology company with a market cap of $857.70 million. The company specialized in the development and commercialization of oncology and hematology drugs. Despite operating through negative earnings currently, Spectrum Pharma is hoping to leverage its product portfolio that consists of both commercial stage and development stage products to address various cancer types.

As of September 13th, 2017, Spectrum Pharmaceuticals, Inc. saw bearish outlooks from analysts. Specifically, 20 investors sold their shares, while an additional 37 reduced their holdings. Altogether, 51.37 million shares of 7.38% less from 55.46 million shares in Q315 were reported.

Amongst 3 analysts covering Spectrum Pharma, all have recommended a “buy” over a sell and a hold. Therefore, the company received 100% of positive reviews.

Featured Image: twitter